☰

Desiree H. Floyd, Ph.D. - Publications

Affiliations: 
2005 Washington University, Saint Louis, St. Louis, MO 
Area:
Molecular Biology
Tree Info Grants Similar researchers PubMed Report error

6/28 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2013 Nichols AS, Floyd DH, Bruinsma SP, Narzinski K, Baranski TJ. Frizzled receptors signal through G proteins. Cellular Signalling. 25: 1468-75. PMID 23524329 DOI: 10.1016/J.Cellsig.2013.03.009  0.45
2012 Su X, Floyd DH, Hughes A, Xiang J, Schneider JG, Uluckan O, Heller E, Deng H, Zou W, Craft CS, Wu K, Hirbe AC, Grabowska D, Eagleton MC, Townsley S, et al. The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. The Journal of Clinical Investigation. 122: 3579-92. PMID 22996695 DOI: 10.1172/Jci38576  0.404
2008 Hernandez JM, Floyd DH, Weilbaecher KN, Green PL, Boris-Lawrie K. Multiple facets of junD gene expression are atypical among AP-1 family members Oncogene. 27: 4757-4767. PMID 18427548 DOI: 10.1038/Onc.2008.120  0.309
2008 Floyd D, Wu K, Hirbe A, Uluckan O, Eagleton M, Conley P, Weilbaecher K. P7. The ADP receptor P2Y12 is expressed in developing osteoclasts and is required for full osteoclast function and tumor associated osteolysis Cancer Treatment Reviews. 34: 15. DOI: 10.1016/J.Ctrv.2008.03.048  0.399
2006 Hagemann IS, Narzinski KD, Floyd DH, Baranski TJ. Random mutagenesis of the complement factor 5a (C5a) receptor N terminus provides a structural constraint for C5a docking. The Journal of Biological Chemistry. 281: 36783-92. PMID 17023413 DOI: 10.1074/Jbc.M607686200  0.693
2003 Floyd DH, Geva A, Bruinsma SP, Overton MC, Blumer KJ, Baranski TJ. C5a receptor oligomerization. II. Fluorescence resonance energy transfer studies of a human G protein-coupled receptor expressed in yeast. The Journal of Biological Chemistry. 278: 35354-61. PMID 12835318 DOI: 10.1074/Jbc.M305607200  0.607
Low-probability matches (unlikely to be authored by this person)
2009 Hirbe AC, Roelofs AJ, Floyd DH, Deng H, Becker SN, Lanigan LG, Apicelli AJ, Xu Z, Prior JL, Eagleton MC, Piwnica-Worms D, Rogers MJ, Weilbaecher K. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone. 44: 908-16. PMID 19442620 DOI: 10.1016/J.Bone.2009.01.010  0.245
2010 Morgan EA, Schneider JG, Baroni TE, Uluçkan O, Heller E, Hurchla MA, Deng H, Floyd D, Berdy A, Prior JL, Piwnica-Worms D, Teitelbaum SL, Ross FP, Weilbaecher KN. Dissection of platelet and myeloid cell defects by conditional targeting of the beta3-integrin subunit. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 24: 1117-27. PMID 19933310 DOI: 10.1096/Fj.09-138420  0.239
2008 Uluçkan O, Eagleton MC, Floyd DH, Morgan EA, Hirbe AC, Kramer M, Dowland N, Prior JL, Piwnica-Worms D, Jeong SS, Chen R, Weilbaecher K. APT102, a novel adpase, cooperates with aspirin to disrupt bone metastasis in mice. Journal of Cellular Biochemistry. 104: 1311-23. PMID 18260128 DOI: 10.1002/Jcb.21709  0.219
2009 Xu Z, Hurchla MA, Deng H, Uluçkan O, Bu F, Berdy A, Eagleton MC, Heller EA, Floyd DH, Dirksen WP, Shu S, Tanaka Y, Fernandez SA, Rosol TJ, Weilbaecher KN. Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. The Journal of Biological Chemistry. 284: 4658-66. PMID 19059914 DOI: 10.1074/Jbc.M804812200  0.215
2017 Li M, Xiao A, Floyd D, Olmez I, Lee J, Godlewski J, Bronisz A, Bhat KPL, Sulman EP, Nakano I, Purow B. CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget. 8: 55319-55331. PMID 28903422 DOI: 10.18632/Oncotarget.19429  0.132
2016 Kingsmore KM, Logsdon DK, Floyd DH, Peirce SM, Purow BW, Munson JM. Interstitial flow differentially increases patient-derived glioblastoma stem cell invasion via CXCR4, CXCL12, and CD44-mediated mechanisms. Integrative Biology : Quantitative Biosciences From Nano to Macro. PMID 27775742 DOI: 10.1039/C6Ib00167J  0.132
2017 Li M, Xiao A, Floyd D, Olmez I, Lee J, Godlewski J, Bronisz A, Bhat KPL, Sulman EP, Nakano I, Purow B. CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget. PMID 28751617 DOI: 10.18632/oncotarget.19429  0.132
2014 Floyd D, Comeau L, Boroda S, Hayes N, Roller D, Xiao A, Friedman A, Boyd L, Gioeli D, Harris T, Harris T, Purow B. PM-02 * DIACYLGLYCEROL KINASE ALPHA INHIBITION PROLONGS SURVIVAL OF MICE WITH PRIMARY AND METASTATIC BRAIN TUMORS Neuro-Oncology. 16: v169-v169. DOI: 10.1093/Neuonc/Nou268.2  0.123
2010 Floyd DH. We can do more Journal of Legal Education. 60: 129-134.  0.12
2009 Kefas B, Comeau L, Floyd DH, Seleverstov O, Godlewski J, Schmittgen T, Jiang J, diPierro CG, Li Y, Chiocca EA, Lee J, Fine H, Abounader R, Lawler S, Purow B. The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 15161-8. PMID 19955368 DOI: 10.1523/Jneurosci.4966-09.2009  0.112
2012 Kijima N, Hosen N, Kagawa N, Hashimoto N, Chiba Y, Kinoshita M, Sugiyama H, Yoshimine T, Kim YZ, Kim KH, Lee EH, Hu B, Sim H, Mohan N, Agudelo-Garcia P, ... ... Floyd DH, et al. LAB-CELL BIOLOGY AND SIGNALING Neuro-Oncology. 14: vi7-vi20. DOI: 10.1093/Neuonc/Nos220  0.096
2012 Floyd DH, Kefas B, Seleverstov O, Mykhaylyk O, Dominguez C, Comeau L, Plank C, Purow B. Alpha-secretase inhibition reduces human glioblastoma stem cell growth in vitro and in vivo by inhibiting Notch. Neuro-Oncology. 14: 1215-26. PMID 22962413 DOI: 10.1093/neuonc/nos157  0.095
2013 Dominguez CL, Floyd DH, Xiao A, Mullins GR, Kefas BA, Xin W, Yacur MN, Abounader R, Lee JK, Wilson GM, Harris TE, Purow BW. Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discovery. 3: 782-97. PMID 23558954 DOI: 10.1158/2159-8290.Cd-12-0215  0.075
2014 Floyd D, Purow B. Micro-masters of glioblastoma biology and therapy: increasingly recognized roles for microRNAs. Neuro-Oncology. 16: 622-7. PMID 24723563 DOI: 10.1093/neuonc/nou049  0.059
2014 Floyd DH, Zhang Y, Dey BK, Kefas B, Breit H, Marks K, Dutta A, Herold-Mende C, Synowitz M, Glass R, Abounader R, Purow BW. Novel anti-apoptotic microRNAs 582-5p and 363 promote human glioblastoma stem cell survival via direct inhibition of caspase 3, caspase 9, and Bim. Plos One. 9: e96239. PMID 24805821 DOI: 10.1371/Journal.Pone.0096239  0.059
2015 Floyd D, Boyd L, Boroda S, Harris T, Purow B. ATPS-22RITANSERIN AND TEMOZOLOMIDE SYNERGIZE AGAINST HUMAN GLIOBLASTOMA IN VITRO AND IN ESTABLISHED TUMORS IN VIVO Neuro-Oncology. 17: v22.5-v23. DOI: 10.1093/Neuonc/Nov204.22  0.056
2014 Clarke RH, Moosa S, Anzivino M, Wang Y, Floyd DH, Purow BW, Lee KS. Sustained radiosensitization of hypoxic glioma cells after oxygen pretreatment in an animal model of glioblastoma and in vitro models of tumor hypoxia. Plos One. 9: e111199. PMID 25350400 DOI: 10.1371/journal.pone.0111199  0.051
2019 Xiao A, Brenneman B, Floyd D, Comeau L, Spurio K, Olmez I, Lee J, Nakano I, Godlewski J, Bronisz A, Kagaya N, Shin-Ya K, Purow B. Statins affect human glioblastoma and other cancers through TGF-β inhibition. Oncotarget. 10: 1716-1728. PMID 30899443 DOI: 10.18632/oncotarget.26733  0.046
2013 Kefas B, Floyd DH, Comeau L, Frisbee A, Dominguez C, Dipierro CG, Guessous F, Abounader R, Purow B. A miR-297/hypoxia/DGK-α axis regulating glioblastoma survival. Neuro-Oncology. 15: 1652-63. PMID 24158111 DOI: 10.1093/Neuonc/Not118  0.038
2017 Olmez I, Love S, Xiao A, Manigat L, Randolph P, McKenna BD, Neal BP, Boroda S, Li M, Brenneman B, Abounader R, Floyd D, Lee J, Nakano I, Godlewski J, et al. Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro-Oncology. PMID 29048560 DOI: 10.1093/Neuonc/Nox119  0.037
2017 Brenneman B, Floyd D, Xiao A, Malyakvo A, Harris T, Purow B. IMMU-51. ASSESSING AND AUGMENTING THE IMMUNE RESPONSE TO GLIOBLASTOMA USING REPURPOSED PHARMACEUTICALS Neuro-Oncology. 19: vi124-vi124. DOI: 10.1093/Neuonc/Nox168.509  0.01
1996 Floyd DH. A "Delicate and Difficult Task": Balancing the Competing Interests of Federal Rule of Evidence 612, the Work Product Doctrine, and the Attorney-Client Privilege Buffalo Law Review. 44: 101-138.  0.01
Hide low-probability matches.